Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study looks inside tumors to see how immunotherapy works

NCT ID NCT02644369

First seen Jun 11, 2026 · Last updated Jun 14, 2026 · Updated 1 time

Summary

This study is for adults with advanced solid tumors (like head and neck, breast, ovarian, or skin cancer) that haven't responded to standard treatments. Researchers want to understand how the drug pembrolizumab changes genes and immune markers in the blood and tumors. The goal is to learn why some people respond to treatment and others don't, not to test a new cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial Melanoma Triple Negative Breast Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.